Relapsed Or Refractory Aml With Idh1 Mutation Therapeutics
1. Rezlidhia patent expiration
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US12275715 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US10532047 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US12053463 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11013734 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11013733 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(13 years from now) | |
| US11497743 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11376246 | RIGEL PHARMS | Inhibiting mutant IDH-1 |
May, 2039
(13 years from now) | |
| US11738018 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(13 years from now) | |
| US10959994 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US10414752 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US10550098 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US11723905 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(13 years from now) | |
| US11498913 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Dosage: CAPSULE
More Information on Dosage
REZLIDHIA family patents
